BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 626 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 626 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20. Following the sale, the chief operating officer directly owned 1,308,161 shares in the company, valued at approximately $341,691,653.20. The trade was a 0.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Stock Performance

Shares of NASDAQ ONC opened at $268.20 on Tuesday. The firm’s 50-day moving average price is $298.56 and its 200-day moving average price is $314.03. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The company has a market cap of $29.43 billion, a PE ratio of 60.00 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ONC. Wells Fargo & Company began coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Guggenheim raised their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada raised their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Finally, Wolfe Research initiated coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $390.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Fiera Capital Corp boosted its stake in shares of BeOne Medicines by 20.1% during the third quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock valued at $8,557,000 after purchasing an additional 4,205 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares in the last quarter. Slow Capital Inc. raised its holdings in BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after purchasing an additional 9,280 shares in the last quarter. Generali Investments Management Co LLC bought a new position in BeOne Medicines in the third quarter worth about $2,726,000. Finally, Capital International Sarl raised its holdings in BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares in the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.